# YUNYING Medicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/yunying-medicine

- Industry: Healthcare
- Headquarters: Shanghai, China
- Website: www.yymedicine.com
- Latest round: Series B (Mar 23, 2026)
- Investors on record: 2

## About

Based in Shanghai, China and founded in 2015, Zhejiang Yunying Medical Technology Co., Ltd., trading as YINYING Medicine, operates as a healthcare company which focuses on molecular diagnosis of cancer. It has sub-branch offices in Jiaxing, Qinghai, and Gansu. The founder and CEO of the company, Daoyun Zhang, graduated from Johns Hopkins University. The co-founder and CTO of the company, Ziying Gong, graduated from the Chinese Academy of Sciences. The company acquired certifications such as GMP Certificate and High-tech enterprise certification. In March 2026, YUNYING Medicine raised Series B+ funding led by Cufe Rising Union.
The company mainly provides tumor gene testing services, which are based on AllNGS™, Alldetect™, and DNAplus™ technologies. AllNGS™ is high specific liquid phase intersection capture technology. DNAplus™ is a plasma free DNA extraction technology used in early tumor screening, immunotherapy decision-making, etc. Yunying Medical has also developed oncolytic virus drugs for pancreatic cancer, colorectal cancer, B-cell lymphoma and melanoma. The company also provides DNA storage tubes, DNA extraction reagents, probe products and other products.
The company generates revenue by providing tumor gene testing services, oncolytic virus drugs, and other related products.
The Series B+ funding raised in March 2026 will be used to further accelerate the company's layout in the field of personalized molecular diagnostics for tumors and related reagent R&D.

## Funding rounds

- Series B, Mar 23, 2026 — Cufe Rising Union
- Series A, Dec 9, 2015 — Kaitai Capital

## Investors

- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Series A
- Cufe Rising Union (https://capitalatlas.ai/funds/cufe-rising-union) — Series B